-+ 0.00%
-+ 0.00%
-+ 0.00%

NRx Pharmaceuticals pushes Kadima dispute into arbitration amid acquisition lawsuit

PUBT·06/25/2026 20:01:19
Listen to the news
NRx Pharmaceuticals pushes Kadima dispute into arbitration amid acquisition lawsuit
  • NRX Pharmaceuticals disclosed it has compelled arbitration with Kadima Neuropsychiatry Institute over a failed HOPE Therapeutics acquisition.
  • The dispute centers on alleged unmet closing conditions, including clear title to assets, cited material adverse change, and other issues.
  • Kadima and its founder, William Feifel, sued to force the deal through specific performance, seeking to join the HOPE clinic network.
  • NRX said it expects San Diego courts to send the case back to arbitration, calling the matter non-material to shareholders.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606251601PRIMZONEFULLFEED9752877) on June 25, 2026, and is solely responsible for the information contained therein.